Clinical Trial Update: Hearing Loss and Dizziness in Patients Receiving Oxaliplatin for Solid Tumors

View source ↗

Summary

The trial update reports cases of hearing loss and dizziness in patients treated with oxaliplatin for solid tumors. This finding highlights neurotoxicity risks …

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Solid Tumors

Drugs mentioned

• Eloxatin (oxaliplatin)

Snippet

Sponsor: Case Comprehensive Cancer Center | Conditions: Neurotoxicity, Unspecified Adult Solid Tumor, Protocol Specific | Status: COMPLETED